The effect of synthetic galanin on plasma glucose, insulin and pancreatic glucagon levels in dogs was studied. Infusion of galanin caused a rapid, reversible and dose-dependent reduction in basal insulin level. A maximal increase in blood glucose level accompanying the insulin decrease was observed when galanin was administered at a dose of 4 µg/kg per h. Pancreatic glucagon levels showed little change compared with basal secretion. These results indicate that galanin is involved in the regulation of glucose through control of insulin secretion.
Introduction
Galanin is a 29 amino acid peptide with a glycine residue at the N-terminus and an alanine amide at the C-terminus which was first isolated from porcine small intestine. 1 Immunohistochemical studies show a wide distribution in the central nervous system. The protein localizes around the hypothalamus and pituitary gland and within nerve cells and nerve fibres of the submucosal and myenteric plexus of digestive organs such as the stomach, duodenum, ileum and colon. 2 -6 Galanin was reported to contract smooth-muscle fibres in the digestive tract, bladder, vascular wall and iris, and to cause sustained elevation of blood glucose in dogs. 1, 5 The underlying mechanism of action is therefore presumed to involve inhibition of insulin secretion. 7, 8 We have studied the effect of galanin on blood glucose and secretion of insulin and pancreatic glucagon in dogs.
Materials and methods

MATERIALS
Five conscious beagle dogs weighing 10.0 -16.5 kg were used for the experiment after being fasted overnight. The experiment was conducted according to the Nagoya City University Graduate School of Medical Sciences Guidelines for the Care and Use of Laboratory Animals. A synthetic form of galanin, provided by Yajima et al. 9 (Faculty of Pharmaceutical Sciences, Kyoto University) was used.
METHODS
To obtain basal values, physiological saline was infused at a rate of 1.5 ml/kg per h T Manabe, Y Okada, H Sawai et al.
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through the forefoot vein, and 2 ml of blood was sampled from the other foot 30 min, 15 min and immediately before injection of galanin. To measure fluctuations in blood glucose, insulin and pancreatic glucagon levels, 0.5 µg/kg, 2 µg/kg, 4 µg/kg and 32 µg/kg per h of galanin was administered intravenously for 30 min. Three days after administration of one concentration, the next experiment was conducted. Two millilitres of blood was collected 10 min, 20 min, 30 min, 45 min, 60 min, 75 min, 90 min, 105 min and 120 min after administration of galanin was started.
Blood glucose levels were measured using the glucose oxidase method. 10 An aliquot of 0.5 ml of blood was centrifuged at 1500 g for 20 min at 4 ºC to obtain serum for measurement of insulin levels using an RIA kit (Dinabot Co., Ltd, Tokyo, Japan). A third aliquot of 1 ml of blood was mixed with 1.2 mg ethylenediamine tetra-acetic acid and pancreatic glucagon levels were measured with an RIA system using pancreatic glucagon-specific antibody OAL-123. 11
STATISTICAL ANALYSIS
Levels of glucose, insulin and pancreatic glucagons were calculated as mean ± SEM. For multiple comparisons, Scheffé's test was used to determine significant differences and Student's t-test was employed to make comparisons within groups.
Results
CONTROL
The control group (n = 5) given physiological saline showed no significant changes in blood glucose and insulin levels over 150 min. Pancreatic glucagon increased significantly after 75 min compared with baseline (Table 1 ).
BLOOD GLUCOSE
When treated with 0.5 µg/kg per h of galanin, no significant change was noted in blood glucose level (Table 1 and Fig. 1 ). In the group treated with 2 µg/kg per h of galanin, however, the level of blood glucose was significantly increased (P < 0.05 and P < 0.01) 20 min after galanin administration compared with the basal value. This significant rise lasted for 45 min after the start of administration. Similar results were seen with 4 µg/kg and 32 µg/kg per h galanin except that the effect was longer lasting -up to 60 min and 90 min after administration, respectively ( Table 1 and Fig. 1 ). Where significant hyperglycaemia was observed, the effect continued after galanin was discontinued, i.e. beyond 30 min.
SERUM INSULIN
Serum insulin levels showed a significant fall (P < 0.05) from the basal value 20 min after commencement of administration of 0.5 µg/kg per h galanin. The results with 2 µg/kg, 4 µg/kg and 32 µg/kg per h galanin showed a faster significant decline (P < 0.05 and P < 0.01) in serum insulin compared to baseline -10 min after administration of galanin. Levels were dose-dependent and rapidly restored to baseline after discontinuation of galanin (Table 1 and Fig. 2 ).
PANCREATIC GLUCAGON
The level of pancreatic glucagon showed a tendency to increase 90 min after administration of 0.5 µg/kg per h galanin, but this was not significant. Administration of 2 µg/kg per h galanin elicited a significant rise in pancreatic glucagons after 120 min (P < 0.01), while doses of 4 µg/kg and 32 µg/kg per h galanin both produced significant increases in pancreatic glucagons 105 min after administration (Table 1 and Fig. 3 ).
OPTIMAL DOSE
A decrease in insulin level accompanied by a maximal increase in blood glucose was seen following a dose of 4 µg/kg per h galanin. 
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Discussion
Since administration of galanin had previously been shown to provoke a rapid and reversible fall in insulin levels, it was concluded to be responsible for the accompanying elevation of blood glucose levels. 7 Using natural galanin extracted from porcine small intestine, McDonald et al. 12 showed 0.5 µg/kg per h to be the threshold value, and 2 µg/kg per h achieved maximum hyperglycaemia. These results generally agree with the results of our study using synthetic galanin. The inhibitory action of galanin on insulin secretion differed between the two studies, however.
Dose-dependence of insulin secretion was not manifest in the study by McDonald et al. 12 and, despite the administration of galanin for 60 min in their study, insulin levels exhibited a slight decline at 10 -20 min and returned to basal level before galanin administration stopped.
Dunning
et al. 13 reported that administration of galanin to anaesthetized dogs did not provoke a significant variation in glucagon levels in arterial blood. In contrast, a significant reversible rise in pancreatic glucagon was seen following treatment via the portal vein. The difference in results may be associated with whether the dogs were anaesthetized or not, but their results showed that administration of 2.5 pmol/kg per min galanin produced a significant change in insulin output and blood glucose level, whereas pancreatic glucagon output did not rise significantly until the dose of galanin was increased to 25 pmol/kg per min. This suggests that elevation of blood glucose is mainly caused by the inhibition of insulin secretion.
Somatostatin differs from galanin as it has an inhibitory effect on the secretion of glucagon as well as insulin. 14 -17 The possibility that inhibition of insulin secretion by galanin is exerted through the intermediary action of somatostatin is therefore unlikely. Dunning et al. 13 reported a decrease in the level of somatostatin in the portal vein when galanin was administered, allowing speculation that somatostatin is not involved in the inhibition of insulin secretion by galanin.
Administration of galanin during stimulated secretion of insulin, using a sustained glucose load of low dose, does not lead to a significant change in blood glucose level, though insulin secretion is significantly suppressed (data not shown). Galanin is therefore thought to be involved in the basal secretion of insulin rather than control of stimulated secretion.
Galanin is a neuropeptide 2 widely distributed in nerve cells and fibres of the submucosal and myenteric plexus of the digestive tract of mammals. It is suggested that galanin may regulate the movement of the digestive tract or the secretion of digestive fluid as an intrinsic peptidergic neuron. 5, 18 With respect to pancreatic secretion, galanin may be involved in neurotic regulation as a neuropeptide, although further studies are needed to investigate this hypothesis.
